Home›Stocks›MRVI

MRVI — structural market context

Maravai LifeSciences Holdings,

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 4. Each line shows the earlier value, the later value and their dates.

Price

Change from the Nov 3 close to the Nov 4 close: +3.62%.

Volume

1.51× its 20-session average on Nov 4.

Includes pre- and post-market trading.

Short interest

Short interest 13.3M shares (settlement Oct 15) vs 13.8M (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Oct 1–Oct 14, published Nov 3): 3 days with fails, largest 105K shares on Oct 14.

Previous file (settlements Sep 15–Sep 30, published Oct 16): no fails listed.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

MRVI events and their magnitude

Latest SEC filing in the event study

Form 4 · other · filed 2026-11-02 · View on sec.gov ↗

…

How the Event Study works →

MRVI short interest & days to cover

SHARES SHORT

13.3M

% OF FLOAT

12.5%

DAYS TO COVER

4.5

CHANGE VS PRIOR

-3.5%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (21d ago)

How short interest and days to cover are measured →

MRVI fails-to-deliver (FTD)

Settlement date	Failed shares	Price
2026-10-14 · 22d	105K	$6.53
2026-10-13 · 23d	4	$7.06
2026-10-08 · 28d	2K	$7.43

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

MRVI analyst ratings

Firm	Action	Rating	Published
Cowen & Co.	initialise	Buy	2026-10-05
UBS	initialise	Neutral	2026-09-09
UBS	hold	Neutral	2026-09-09
UBS	price_target	—	2026-09-09

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is MRVI's short interest?

As of the FINRA settlement date 2026-10-15, MRVI had 13.3M shares sold short — 12.5% of its float, with 4.5 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.

What do analysts say about MRVI?

The most recent action: Cowen & Co. initialise to Buy on 2026-10-05. Rating actions are shown as published by the firms; they are not graded here.

Is this page telling me to buy or sell MRVI?

No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.

All covered stocks Short Interest & FTD tracker Insider Buying tracker The platform

Other companies in the same SEC industry: Pharmaceutical Preparations

ACRS · Aclaris Therapeutics, Inc.ALNY · Alnylam Pharmaceuticals, Inc.DYN · Dyne Therapeutics, Inc.KNSA · Kiniksa Pharmaceuticals Intern LQDA · Liquidia Corporation NVS · Novartis AG

Industry: SIC code 2834 as recorded on SEC EDGAR.

All tickers starting with M →

MRVI: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.